-
公开(公告)号：US20060223794A1
公开(公告)日：2006-10-05
申请号：US10551014
申请日：2004-03-31
IPC分类号： A61K31/551 , C07D498/02
CPC分类号： A61K9/145 , A61K9/0004 , A61K9/1617 , A61K9/1652 , A61K9/2077 , A61K9/209 , A61K31/167 , A61K31/192 , A61K31/4166 , A61K31/55 , A61K31/616 , A61K47/10 , A61K47/32 , C07C51/412 , C07C51/43 , C07C233/25 , C07D223/26 , C07D233/74 , C07D495/04 , C07C53/06 , C07C53/10 , C07C57/30 , C07C61/135
摘要： The invention provides novel soluble olanzapine forms. These forms include salts, co-crystals, and solvates of olanzapine. The invention also provides novel pharmaceutical compositions comprising these novel soluble forms and related methods of treatment. Compositions and methods of the invention of the invention are useful in the treatment of psychosis and functional bowel disorders.
摘要翻译： 本发明提供新的可溶性奥氮平形式。 这些形式包括奥氮平的盐，共晶体和溶剂合物。 本发明还提供包含这些新型可溶形式和相关治疗方法的新型药物组合物。 本发明的组合物和方法可用于治疗精神病和功能性肠病。
-
公开(公告)号：US20120015993A1
公开(公告)日：2012-01-19
申请号：US10599010
申请日：2005-03-17
申请人： Magali Bourghol Hickey , Matthew L. Peterson , Örn Almarsson , Michael J. Zaworotko , Tanise Shattock , Jennifer McMahon , Joanna Bis , Julius F. Remenar , Mark Tawa
发明人： Magali Bourghol Hickey , Matthew L. Peterson , Örn Almarsson , Michael J. Zaworotko , Tanise Shattock , Jennifer McMahon , Joanna Bis , Julius F. Remenar , Mark Tawa
IPC分类号： A61K31/4196 , C07D249/08 , A61P35/00
CPC分类号： C07C255/60 , C07B2200/07 , C07B2200/13 , C07C311/37 , C07C317/46 , C07D211/32 , C07D217/26 , C07D231/12 , C07D239/553 , C07D249/08 , C07D401/12 , C07D471/14
摘要： Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
摘要翻译： 本发明提供比卡鲁胺，5-氟尿嘧啶，多奈哌齐，阿那曲唑，奈非那韦，米氮氮平，兰索拉唑和坦索罗辛或其衍生物的结晶盐，多晶型物，溶剂合物和水合物。 还提供了制备和使用它们的方法。
-
公开(公告)号：US20070026078A1
公开(公告)日：2007-02-01
申请号：US10660202
申请日：2003-09-11
申请人： Orn Almarsson , Magali Bourghol Hickey , Matthew Peterson , Michael Zaworotko , Brian Moulton , Nair Rodriguez-Hornedo
发明人： Orn Almarsson , Magali Bourghol Hickey , Matthew Peterson , Michael Zaworotko , Brian Moulton , Nair Rodriguez-Hornedo
IPC分类号： A61K9/14
CPC分类号： A61K9/145 , A61K9/0004 , A61K9/1617 , A61K9/1652 , A61K9/2077 , A61K9/209 , A61K31/167 , A61K31/192 , A61K31/4166 , A61K31/55 , A61K31/616 , A61K47/10 , A61K47/32 , C07C51/412 , C07C51/43 , C07C233/25 , C07D223/26 , C07D233/74 , C07D495/04 , C07C53/06 , C07C53/10 , C07C57/30 , C07C61/135
摘要： A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
摘要翻译： 一种药物组合物，其包含API和共晶体形成剂的共晶体; 其中API具有至少一个选自醚，硫醚，醇，硫醇，醛，酮，硫酮，硝酸酯，磷酸酯，硫代磷酸酯，酯，硫酯，硫酸酯，羧酸，膦酸，次膦酸， 磺酸，酰胺，伯胺，仲胺，氨，叔胺，sp2胺，硫氰酸酯，氨腈，肟，腈重氮，有机卤化物，硝基，S-杂环，噻吩，n-杂环，吡咯， ，呋喃，环氧化物，过氧化物，异羟肟酸，咪唑，吡啶和共结晶形成物具有至少一个选自胺，酰胺，吡啶，咪唑，吲哚，吡咯烷，羰基，羧基，羟基，苯酚，砜，磺酰基 ，巯基和甲基硫基，使得API和共结晶形成体能够在结晶条件下从溶液相共结晶。
-
公开(公告)号：US07803786B2
公开(公告)日：2010-09-28
申请号：US11629807
申请日：2005-06-16
申请人： Jennifer McMahon , Matthew Peterson , Michael J. Zaworotko , Tanise Shattock , Magali Bourghol Hickey
发明人： Jennifer McMahon , Matthew Peterson , Michael J. Zaworotko , Tanise Shattock , Magali Bourghol Hickey
IPC分类号： A61K31/7028 , A61K31/55 , A61K31/175 , A61K31/4196 , C07D223/18 , C07H19/048 , C07C275/00
CPC分类号： A61K45/06 , A61K9/145 , A61K38/17 , A61K2300/00
摘要： The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.
摘要翻译： 本发明包括包含API和共晶体形成剂的共晶体的药物组合物及其制备和使用方法。
-
公开(公告)号：US07671093B2
公开(公告)日：2010-03-02
申请号：US11139245
申请日：2005-05-27
IPC分类号： A61K31/165
CPC分类号： A61K31/165 , A61K9/145 , A61K31/191 , C07C55/10 , C07C57/15 , C07C317/44 , A61K2300/00
摘要： A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.
摘要翻译： 描述了包含API，第一共晶体形成器和与所述第一共晶体形成体同构取代的第二共晶体形成器的混合共晶体。 还描述了包含混合共晶的药物组合物，制备混合共晶体的方法和使用混合共晶体的方法。
-
公开(公告)号：US20050267209A1
公开(公告)日：2005-12-01
申请号：US11139245
申请日：2005-05-27
IPC分类号： A01N37/18 , A61K9/00 , A61K9/20 , A61K9/26 , A61K31/165 , A61K31/191 , A61K31/205
CPC分类号： A61K31/165 , A61K9/145 , A61K31/191 , C07C55/10 , C07C57/15 , C07C317/44 , A61K2300/00
摘要： A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.
摘要翻译： 描述了包含API，第一共晶体形成器和与所述第一共晶体形成器同构取代的第二共晶体形成器的混合共晶体。 还描述了包含混合共晶的药物组合物，制备混合共晶体的方法和使用混合共晶体的方法。
-
公开(公告)号：US08436029B2
公开(公告)日：2013-05-07
申请号：US10599010
申请日：2005-03-17
申请人： Magali Bourghol Hickey , Matthew L. Peterson , Örn Almarsson , Michael J. Zaworotko , Tanise Shattock , Julius F. Remenar , Mark Tawa
发明人： Magali Bourghol Hickey , Matthew L. Peterson , Örn Almarsson , Michael J. Zaworotko , Tanise Shattock , Julius F. Remenar , Mark Tawa
IPC分类号： A01N43/64 , A61K31/41 , C07D473/00
CPC分类号： C07C255/60 , C07B2200/07 , C07B2200/13 , C07C311/37 , C07C317/46 , C07D211/32 , C07D217/26 , C07D231/12 , C07D239/553 , C07D249/08 , C07D401/12 , C07D471/14
摘要： Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
摘要翻译： 本发明提供比卡鲁胺，5-氟尿嘧啶，多奈哌齐，阿那曲唑，奈非那韦，米氮氮平，兰索拉唑和坦索罗辛或其衍生物的结晶盐，多晶型物，溶剂合物和水合物。 还提供了制备和使用它们的方法。
-
公开(公告)号：US08338646B2
公开(公告)日：2012-12-25
申请号：US12708998
申请日：2010-02-19
IPC分类号： C07C233/65
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
公开(公告)号：US20100311701A1
公开(公告)日：2010-12-09
申请号：US12792415
申请日：2010-06-02
申请人： Orn Almarsson , Magali Bourghol Hickey , Matthew Peterson , Michael J. Zaworotko , Brian Moulton , Nair Rodriguez-Hornedo
发明人： Orn Almarsson , Magali Bourghol Hickey , Matthew Peterson , Michael J. Zaworotko , Brian Moulton , Nair Rodriguez-Hornedo
IPC分类号： A61K31/616 , A61K31/415 , A61K31/455 , A61K31/335 , A61K31/357 , A61K31/5513 , A61K31/4196 , A61K31/194 , A61K31/165 , A61K31/191 , A61K31/513 , A61K31/17 , A61K31/549 , A61K31/167 , A61K31/444 , A61K31/4166 , A61K31/4412 , A61K31/192 , A61K31/55 , A61K31/12
CPC分类号： A61K31/12 , A61K31/165 , A61K31/167 , A61K31/17 , A61K31/191 , A61K31/192 , A61K31/194 , A61K31/335 , A61K31/357 , A61K31/415 , A61K31/4166 , A61K31/4196 , A61K31/4412 , A61K31/444 , A61K31/455 , A61K31/513 , A61K31/549 , A61K31/55 , A61K31/5513 , A61K31/616
摘要： A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
摘要翻译： 一种药物组合物，其包含API和共晶体形成剂的共晶体; 其中API具有至少一个选自醚，硫醚，醇，硫醇，醛，酮，硫酮，硝酸酯，磷酸酯，硫代磷酸酯，酯，硫酯，硫酸酯，羧酸，膦酸，次膦酸， 磺酸，酰胺，伯胺，仲胺，氨，叔胺，亚胺，硫氰酸酯，氨腈，肟，腈重氮，有机卤化物，硝基，S-杂环，噻吩，N-杂环，吡咯，O-杂环， 呋喃，环氧化物，过氧化物，异羟肟酸，咪唑，吡啶和共结晶形成物具有至少一个选自胺，酰胺，吡啶，咪唑，吲哚，吡咯烷，羰基，羧基，羟基，苯酚，砜，磺酰基， 巯基和甲基硫基，使得API和共晶体形成剂能够在结晶条件下从溶液相共结晶。
-
公开(公告)号：US20090018202A1
公开(公告)日：2009-01-15
申请号：US10587086
申请日：2005-02-01
IPC分类号： A61K31/165 , C07C231/00 , A61P25/00
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.037 秒)
